Caris Life Sciences, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On June 7, 2026, Caris Life Sciences amended its April 1, 2026 financing agreement with Blue Owl Capital Corporation and multiple lenders. The amendment adds Schedule 1.1(c) and modifies Section 6.5(f) to permit repurchase of Qualified Capital Stock, subject to conditions specified in the new schedule (not detailed in this excerpt). No dollar amounts, repurchase limits, or specific conditions are disclosed in the amendment itself.
Why this rating
Procedural amendment permitting stock buybacks under undisclosed conditions. No financial impact quantified; scope and materiality unknown relative to $3.9B market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.